Alternative investment strategies
Specialist advisory for life sciences mandates requiring institutional-grade documentation, stakeholder alignment, and disciplined execution from mandate design through close.
All industries
Industry advisory
Life Sciences
Financing innovation across biotech, pharma, and medtech
Capital structuring for pharmaceutical manufacturing, biotech, and the localisation of medicine supply.
Discuss your sector mandate with our Dubai team.Overview
Financing innovation across biotech, pharma, and medtech
We support life sciences companies and investors with alternative investment vehicles, clinical-stage risk assessment, and capital strategies for R&D-intensive growth.
Pharmaceutical localisation is a stated objective across the Gulf, driven by supply security and diversification. Financing depends on regulatory approval pathways, procurement commitments, and technology transfer arrangements with international partners.
Financing innovation across biotech, pharma, and medtech
- 4
Advisory pillars
Capital, risk, funds, and credit enhancement
- GCC
Regulatory depth
Frameworks across GCC and wider Middle East markets
- 360°
Mandate coverage
Strategy to execution in life sciences
- 26
Sector breadth
Cross-industry insight applied to your mandate
Sector perspective
Gulf capital meets life sciences opportunity
Capital structuring for pharmaceutical manufacturing, biotech, and the localisation of medicine supply.
Key challenges
Financing innovation across biotech, pharma, and medtech
Capital structuring for pharmaceutical manufacturing, biotech, and the localisation of medicine supply.
Structuring capital for life sciences assets amid evolving regulation and market volatility
Aligning innovation funding, IP ownership, and regulatory approval timelines with long-dated capital structures
Balancing long-dated life sciences cash flows with short-term liquidity and covenant expectations
Bridging clinical, regulatory, and technology-obsolescence risk with staged capital and milestone financing
Highlights
Financing innovation across biotech, pharma, and medtech
Capital structuring for pharmaceutical manufacturing, biotech, and the localisation of medicine supply.
Investment due diligence
Integrated risk frameworks covering political, regulatory, operational, and financial exposure — tailored to how life sciences assets perform across jurisdictions and market cycles.
Gulf capital access
Direct connectivity to Gulf sovereign and institutional investors, family offices, and guarantee providers actively seeking well-structured life sciences exposure.
Multi-jurisdictional execution
End-to-end support for multi-jurisdictional life sciences programs — from feasibility and due diligence through capital mobilization, monitoring, and portfolio reporting.
Expertise
Financing innovation across biotech, pharma, and medtech
Capital structuring for pharmaceutical manufacturing, biotech, and the localisation of medicine supply.
Advisory frameworks aligned with GCC regulatory and international institutional standards.
Our approach
We support life sciences companies and investors with alternative investment vehicles, clinical-stage risk assessment, and capital strategies for R&D-intensive growth. Our life sciences practice centers on milestone-based institutional capital advisory — translating sector complexity into bankable mandates, confident board decisions, and repeatable execution across GCC and wider Middle East markets.
“Capital structuring for pharmaceutical manufacturing, biotech, and the localisation of medicine supply.”
Mandate execution
From assessment to capital mobilization
Our Dubai advisory team structures life sciences mandates with the discipline sovereign and institutional investors and development finance partners require.
Our process
A disciplined approach to capital advisory
We integrate financial expertise, policy insight, and strategic advisory capabilities to help clients structure bankable projects, mitigate risk, and mobilize capital with confidence.
Start a sector conversation
Tell us about your capital requirement, risk profile, or structuring objective.
Email us directly
[email protected]Assess
Diagnose life sciences capital requirements, stakeholder dynamics, and regulatory milestones, IP, and commercialization paths before structuring.
Assess 01
Structure
Design bankable milestone tranches and institutional co-investment aligned with life sciences cash flows and covenant standards.
Structure 02
Mobilize
Connect Gulf sovereign, institutional, family-office, and development finance sources; coordinate due diligence and term sheet negotiation.
Mobilize 03
Monitor
Establish reporting cadences and oversight for regulatory, clinical, and commercialization milestones so life sciences investments remain transparent to financiers.
Monitor 04
Advisory frameworks aligned with GCC regulatory and international institutional standards.
Latest insights
Financing innovation across biotech, pharma, and medtech
Capital structuring for pharmaceutical manufacturing, biotech, and the localisation of medicine supply.
Outcomes
Outcomes
Capital structuring for pharmaceutical manufacturing, biotech, and the localisation of medicine supply.
Milestone-based and institutional capital structures matched to R&D and commercialization phases
Regulatory, IP, and technology risk diligence structured for staged investment decisions
Phased capital release tied to regulatory, clinical, or commercialization milestones
Milestone, clinical, and impact reporting suitable for institutional and DFI oversight
Related industries
All industries
Capital structuring for pharmaceutical manufacturing, biotech, and the localisation of medicine supply.
Sector mandate
Discuss your sector requirement
Capital structuring for pharmaceutical manufacturing, biotech, and the localisation of medicine supply.
Headquarters
Consultinghouse
Discuss your capital or investment mandate
Dubai · Munich
Industry advisory
Advisory frameworks aligned with GCC regulatory and international institutional standards.
Start a sector conversation
Tell us about your capital requirement, risk profile, or structuring objective.
Capital · ImpactGulf capital · Regional mandates
Explore expertise